A new immunotherapy using established cytotoxic T lymphocyte targeting LY6K was studied in lung and oesophageal cancer cell lines (Ishikawa et al, 2007; Kono et al, 2009), meaning that LY6K is a promising target for BC immunotherapy. Here, LY6K is linked to carcinoma of esophagus.